Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1237-1244

  Jeong, Han Sin ^a   Man, Ki Chung ^a   Son, Young Ik ^a   Joon, Young Choi ^a   Hyung, Jin Kim ^a   Young, Hyeh Ko ^a   Baek, Chung Hwan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

18F FDG; CT scans; PET CT; Salivary gland cancers; Treatment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM; IOPROMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALIVARY GLAND CANCER; STANDARD; TREATMENT PLANNING; IMAGE QUALITY; METHODOLOGY; MIDDLE AGED; SALIVARY GLAND TUMOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOPHARMACEUTICALS; SALIVARY GLAND NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547764787     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.041350     Document Type: Article

References (23)

1. Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002;8:229-240.
2. Kokemueller H, Swennen G, Brueggemann N, Brachvogel P, Eckardt A, Hausamen JE. Epithelial malignancies of the salivary glands: clinical experience of a single institution - a review. Int J Oral Maxillofac Surg. 2004;33:423-432.
3. Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg. 2005;133:702-708.
4. Kim KH, Sung MW, Yun JB, et al. The significance of CT scan or MRI in the evaluation of salivary gland tumors. Auris Nasus Larynx. 1998;25:397-402.
5. 201Tl SPET. Nucl Med Commun. 2000;21:277-284.
6. Koyuncu M, Sesen T, Akan H, et al. Comparison of computed tomography and magnetic resonance imaging in the diagnosis of parotid tumors. Otolaryngol Head Neck Surg. 2003;129:726-732.
7. Tabor EK, Curtin HD. MR of the salivary glands. Radiol Clin North Am. 1989;27:379-392.
8. Traxler M, Hajek P, Solar P, Ulm C. Magnetic resonance in lesions of the parotid gland. Int J Oral Maxillofac Surg. 1991;20:170-174.
9. Yabuuchi H, Fukuya T, Tajima T, Hachitanda Y, Tomita K, Koga M. Salivary gland tumors: diagnostic value of gadolinium-enhanced dynamic MR imaging with histopathologic correlation. Radiology. 2003;226:345-354.
10. Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin. 1999;38:312-318.
11. Keyes JW Jr, Harkness BA, Greven KM, Williams DW 3rd, Watson NE Jr, McGuirt WF. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99-102.
12. McGuirt WF, Keyes JW Jr, Greven KM, Williams DW 3rd, Watson NE Jr, Cappellari JO. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope. 1995;105:579-584.
13. Okamura T, Kawabe J, Koyama K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol Suppl. 1998;538:209-213.
14. Uchida Y, Minoshima S, Kawata T, et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clin Nucl Med. 2005;30:170-176.
15. 18F-FDG PET/CT play a role in the differential diagnosis of parotid masses. Panminerva Med. 2005;47:187-189.
16. Otsuka H, Graham MM, Kogame M, Nishitani H. The impact of FDG-PET in the management of patients with salivary gland malignancy. Ann Nucl Med. 2005;19:691-694.
17. Lim YC, Lee SY, Kim K, et al. Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol. 2005;41:1021-1027.
18. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
19. Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR. 1992;I58:961-969.
20. 18F-FDG PET for patients with salivary gland malignancies. J Nucl Med. 2007;48:240-246.
21. 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck. 2007;29:203-210.
22. 18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005;23:7654-7659.
23. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun. 2006;27:795-802.